The recent rise of generative Artificial Intelligence (AI) has revolutionized the approach to innovative solutions for the Life Sciences industry. ChatGPT (GPT-4), an advanced large language model powered by AI, may have the ability to greatly benefit the pharmaceutical industry. With its ability to understand and generate human-like text, the industry may one day be able to leverage ChatGPT to streamline operations, enhance R&D efforts, improve customer support, and aid in regulatory compliance.
PM360 asked experts in data analytics about how the process behind collecting and analyzing data is changing, including these four key questions:
- How is the advancement of artificial intelligence, natural language processing, machine learning, and deep learning impacting the data analytics landscape?
- How has the rise of concern for data privacy and the implementation of the EU’s General Data Protection Regulation (GDPR) affected pharma’s ability to collect or use data?
- What can organizations do to help make their employees more data literate? Ultimately, how do you make everyone comfortable using data analytics?
- What is the future of data analytics? How else is data collection, analyzation, visualization, implementation, etc., likely to change in 2019 and beyond?